News summary

Traded: Venture Capital 🦄 on Instagram: "San Francisco-based Remedy Robotics, a healthcare and physical AI company developing robotic systems for cardiovascular and endovascular procedures, raised $62 million in Series B funding in a round led by DCVC, with participation from UC Investments, Skip Capital, Hostplus, Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures. Co-founded by CEO Dr. David Bell and CTO Jake Sganga, the company develops the N1 System, an AI-enabled robotic platform designed to support remote, on-site and autonomous vascular procedures. Remedy Robotics will use the funding to accelerate a pivotal clinical trial with the University of California, advance toward FDA approval for neurovascular intervention, deploy prototype N1 Systems across its clinical partner network and further develop its AI and autonomous capabilities. FOUNDERS: Dr. David Bell & Jake Sganga INVESTORS: DCVC, UC Investments, Skip Capital, Hostplus, Build Collective by Tony Fadell, Blackbird, Divergent Capital, KdT Ventures ROUND: Series B AMOUNT: $62,000,000 HQ: San Francisco, California #VentureCapital #RemedyRobotics #DrDavidBell #JakeSganga #TradedVC"

Source: traderVC • Published: 16 Nov 2026, 20:58

Summarized by Masters of Longevity from traderVC.

Remedy Robotics raised $62 million to advance its AI vascular robotic platform.

Traded: Venture Capital 🦄 on Instagram: "San Francisco-based Remedy Robotics, a healthcare and physical AI company developing robotic systems for cardiovascular and endovascular procedures, raised $62 million in Series B funding in a round led by DCVC, with participation from UC Investments, Skip Capital, Hostplus, Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures. Co-founded by CEO Dr. David Bell and CTO Jake Sganga, the company develops the N1 System, an AI-enabled robotic platform designed to support remote, on-site and autonomous vascular procedures. Remedy Robotics will use the funding to accelerate a pivotal clinical trial with the University of California, advance toward FDA approval for neurovascular intervention, deploy prototype N1 Systems across its clinical partner network and further develop its AI and autonomous capabilities. FOUNDERS: Dr. David Bell & Jake Sganga INVESTORS: DCVC, UC Investments, Skip Capital, Hostplus, Build Collective by Tony Fadell, Blackbird, Divergent Capital, KdT Ventures ROUND: Series B AMOUNT: $62,000,000 HQ: San Francisco, California #VentureCapital #RemedyRobotics #DrDavidBell #JakeSganga #TradedVC"
Key Takeaways
  • Funding is to finance a pivotal trial with UC.
  • Company is pursuing FDA approval for neurovascular intervention.
  • N1 prototypes are to be deployed at clinical partner sites.
Read the full article at traderVC ↗

Continue exploring

Recommended MoL Picks

MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.